|

Devimistat Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Alpha-Lipoic Acid Analogue CPI-613, CPI 613, CPI-613

Pipeline

Phase 2: 1

Top Sponsors

  • Northwestern University1

Indications

  • Refractory Urothelial Carcinoma1
  • Refractory Gastroesophageal Junction Adenocarcinoma1
  • Refractory Colorectal Carcinoma1
  • Refractory Biliary Tract Carcinoma1
  • Metastatic Lung Adenocarcinoma1

Chicago, Illinois1 trial

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.